2022 Report to Shareholders

Record revenue and profit growth.

Message from the Chairman and CEO

Dear shareholder,

At Cogstate, we are on a mission to democratize brain health.

We passionately believe that easy-to-use, low-cost, non-invasive, sensitive measurements provide a pathway to improved brain health globally.

Guided by the mantra of Brain Health for All, we combine proven science with disruptive digital innovation to make the measurement of cognition as simple, standardised, actionable and common as the measurement of blood pressure.

Over the last year, Cogstate has remained focused on this mission and has achieved true momentum as we continued to build upon and leverage the gains in commercial, operational, scientific and technological capabilities made by the company in recent years. We are recognised as a global leader in cognitive science and have evolved into a fast-growing, profitable business.

READ MORE

FY22 Financial Highlights

Strong earnings growth and solid cash position

(all figures in US$)

82.5m
Record clinical sales contracts executed
139.1m
Record contracted future revenue
45.0m
Record Group Revenue
10.7m
Record PBT
9.0m
Strong operating net cash flow
28.7m
Net Cash balance

Watch our Investor webcast and download the Cogstate Annual Report 2022

INVESTOR WEBCAST          2022 ANNUAL REPORT

Receive Investor Updates

Please fill out the form to subscribe